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Abstract
Background: HIV-1 can be inhibited by RNA interference in vitro through the expression of short hairpin RNAs
(shRNAs) that target conserved genome sequences. In silico shRNA design for HIV has lacked a detailed study of
virus variability constituting a possible breaking point in a clinical setting. We designed shRNAs against HIV-1
considering the variability observed in naïve and drug-resistant isolates available at public databases.
Methods: A Bioperl-based algorithm was developed to automatically scan multiple sequence alignments of HIV,
while evaluating the possibility of identifying dominant and subdominant viral variants that could be used as
efficient silencing molecules. Student t-test and Bonferroni Dunn correction test were used to assess statistical
significance of our findings.
Results: Our in silico approach identified the most common viral variants within highly conserved genome regions,
with a calculated free energy of ≥ -6.6 kcal/mol. This is crucial for strand loading to RISC complex and for a
predicted silencing efficiency score, which could be used in combination for achieving over 90% silencing.
Resistant and naïve isolate variability revealed that the most frequent shRNA per region targets a maximum of 85%
of viral sequences. Adding more divergent sequences maintained this percentage. Specific sequence features that
have been found to be related with higher silencing efficiency were hardly accomplished in conserved regions,
even when lower entropy values correlated with better scores. We identified a conserved region among most
HIV-1 genomes, which meets as many sequence features for efficient silencing.
Conclusions: HIV-1 variability is an obstacle to achieving absolute silencing using shRNAs designed against a
consensus sequence, mainly because there are many functional viral variants. Our shRNA cocktail could be truly
effective at silencing dominant and subdominant naïve viral variants. Additionally, resistant isolates might be
targeted under specific antiretroviral selective pressure, but in both cases these should be tested exhaustively prior
to clinical use.
Background
Despite the advent of highly active antiretroviral therapy
(HAART), human immunodeficiency virus (HIV-1) is
still a matter of concern for public health [1]. The major
obstacle to finding a cure lies in the integration of the
viral genome, by virtue of which the virus will always
have a chance to restart the infection [2]. The over-
whelming genetic variability of HIV-1 is mainly due to
the error-prone nature of reverse transcriptase (RT) [3].
Other factors are also responsible for generating
quasispecies, and usually a combination of factors
-genetic (e. g. HLA type), immunological (e. g. CD8+
cytotoxic T lymphocytes selective pressure) and viral
(e. g. HIV type, subtype, recombination events) among
others- contributes to the exhaustion of the immune
system [4,5]. Moreover, the virus has an innate ability to
accumulate mutations that are readily accepted by its
flexible proteins [6]. Collectively, these factors help the
virus to overcome HAART [7]. Clearly, effective strate-
gies are needed to combat each replication-competent
viral variant that may emerge under any circumstances
or selective pressure [8,9]. Although HAART saves
thousands of lives, resistant variants emerge, even
though multiple key steps in the viral replication cycle
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have shown persistent viral replication, even under suc-
cessful HAART [11,12].
RNA interference (RNAi) is an evolutionarily con-
served naturally occurring eukaryotic process by which
double-stranded RNA (dsRNA) triggers post-transcrip-
tional gene silencing [13]. Research during the last dec-
ade has focused on the possibility of using it to treat
various diseases [14]. In fact, several in vitro and in vivo
RNAi approaches have proven effective at inhibiting
HIV-1 [15-17], and such studies have shown that repli-
cation is potently inhibited beyond initial replication
only when multiple conserved regions in the viral gen-
ome are targeted simultaneously [18,19]. However, even
though HIV-1 has been inhibited in vivo in a humanized
mouse model [20], there is no absolute certainty this
will extrapolate to humans. Key differences between
mouse models and humans may influence the viral
population and its evolution, especially if complete inhi-
bition is not achieved.
shRNA design to date has been based on studies of
HIV variability that have focused on conserved regions
and multiple sequence alignments (MSAs) [21], in
which the HXB2 reference genome has been used to
select the consensus silencing sequence. Efficient silen-
cing molecules have also been selected by in vitro
screening [17]. Previous studies analyzing 170 and 495
full-length genomes identified 19 and 216 target
sequences respectively, showing that a greater number
of viral genomes provides more evidence for variability
[18,22]. Other authors have analyzed the conservation of
unique targets from gene sequence fragments of 19
nucleotides [23]. However, 75% conservation among its
genomes still allows the virus 25% variability, which it
can use to escape from shRNA-based silencing. This
highlights the importance of analyzing not only pre-
viously reported parameters of silencing efficiency
[24,25], but also enough sequences to represent the
actual viral variability. We addressed this issue by
including in our analysis resistant isolates and more
than 1000 viral genomes representing the M group viral
divergence. The principal target was RT, but we further
analyzed complete genome sequences. In silico studies
can produce accurate enough approximations to guide
better experimental approaches; thus, with this in mind,
we developed an in silico approach for identification of
the best HIV silencing molecules. Our in silico approach
scanned multiple HIV-1 aligned genomes in search for
the most frequent (dominant and subdominant) nucleo-
tide variants in several conserved regions instead of
identifying a single consensus sequence for each, in
o r d e rt ob ea b l et ou s et h e ma l ls i m u l t a n e o u s l yi na
combination cocktail. These variants were analyzed fol-
lowing Zhou and Zeng’s [24] parameters in order to
select the ones that could be efficient shRNAs, given a
silencing score and an exhaustive search for off-target
effects.
Results
Conserved regions and prevalent drug-resistant
mutations
The homology searches of the RT_Rtv cd01645 protein
domain were used for a BLAST search against the refer-
ence HIV-1 POL protein in the NCBI Conserved
Domain Database (CDD) with a cut-off of 1e-85. Within
this domain, nine subregions were mapped that were
associated with DNA binding sites, dNTP binding sites,
reverse transcriptase inhibitor (RTI) binding sites, active
site residues with no other annotations, and the motif
YMDD (Figure 1). Highly prevalent drug-resistant muta-
tions located within or adjacent to these regions were
identified. Table 1 shows the selected regions with their
wild type residues and drug-resistant substitutions with
corresponding prevalence based on HIVRT&PrDB data.
Positions were mapped with respect to the HXB2
Figure 1 Crystallographic structure of RT indicating Selected
Regions. (a) RT crystallographic structure 2ZD1 (1.8 Å) highlights
the residues within the selected regions, Dark gray = p66 subunit,
light gray = p55, dark blue = active site residues involved in dNTP
binding (K65, R72, D110, V111, G112, D113, A114, Y115, Q151), green
= active site residues involved in DNA binding (L74, V75, D76, R78,
N81, E89, Q91, L92, I94, G152, K154, P157, M230, G231), purple =
active site residues with no specific annotations (W24, P25, F61),
pink = YMDD motif (Y183, M184, D185, D186), and light blue =
residues involved in NNRTI binding (L100, K101, K102, K103, V179,
Y188, G190, F227; not conserved). Ribbon shows continuity between
amino acid chains.
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for each MSA.
Sequence retrieval and MSAs
A total of 2,264 sequences from the non-specific first line
regimen were downloaded fromH I V R T & P r D Ba n da l i g n e d .
In addition, four specific MSA from specific regimens were
generated independently, but with caution on not including
sequences with previous treatment history: Stavudine-Lami-
vudine-Nevirapine (D4T-3TC-NVP) MSA (91 sequences),
Zidovudine-Lamivudine-Efavirenz (ZDV-3TC-EFV) MSA
(1,381 sequences), Zidovudine-Lamivudine-Abacavir (ZDV-
3TC-ABC) (52 sequences) and Zidovufine-Lamivudine-
Nevirapine (ZDV-3TC-NVP) (212 sequences). Six MSA
f r o mL o sA l a m o sH I Vd a t a b a s e sw e r eu s e dt oa s s e s st h e
impact of viral diversity: three from only the pol gene
(B subtype no recombinants, 778 sequences; Group M
plus recombinants, 1206 sequences; all subtypes,
1250 sequences) and three from complete HIV genomes
(B subtype no recombinants, 790 sequences; Group M plus
Table 1 Target regions within Conserved Domain RT_rtv
Region
No.
Residue
Position
(wild type)
Residue
(wild type)
Function
annotation
HXB2
coordinates
Mutation in RT
2
and prevalence
3
Evaluated Region
in MA
4
1 24, 25 W,P DBS 2619-2622 - 2610 - 2630
2 60 V - 2727 I(14) 2700 - 2760
61 F AS 2730 -
62 A - 2733 V(14)
64 K - 2736 R(1.9)
65 K dBS 2742 R(2.1)
67 D - 2748 N(38), G(2.5)
37 2R dBS 2763 - 2750 -2800
74-76, 78, 81 L,V,D,R,N DBS-AS 2769-2790 -
48 9E DBS-AS 2814 - 2800 - 2840
90 V - 2828 I(3.3)
91,92,94 Q,L,I DBS-AS 2820-2829 -
5 100-103 L,K,K,K NNBS 2847-2856 - 2835 - 2870
6 110-115 D,V,G,D,A,
Y
dBS-AS 2877-2892 - 2865 - 2905
7 151 Q dBS-AS 3000 M(3.4) 2985-3020
152,154,157 G,K,P DBS-AS 3003-3018 -
8 178 I - 3081 M(7.5), L(6.4) 3070-3130
179 V NNBS 3084 I(7.9), D(1.3)
181 Y - 3090 C(14)
183 Y NNBS-DBS-AS 3096 -
184 M variable 3099 V(50), I(1.4)
185 D dBS-AS 3102 -
186 D AS 3105 -
188 Y NNBS 3111 L(3.5)
190 G NNBS 3117 -
9 227 F NNBS 3228 L(1.6) 3210-3255
228 L - 3231 H(12), R(4.2)
230 M DBS-AS 3237 L(1.8)
231 G DBS-AS 3240 -
1Positions according to the HXB2 reference genome numbering system (coordinate map).
2RT drug resistance mutations prevalence was calculated from 17,167 sequences exposed to either of these drug types (HIV Drug Resistance Database).
3Mutation prevalence (percent) data are available at the HIV Drug Resistance Database.
4MSA: multiple alignment.
In bold, residues directly involved in enzyme activity
DBS, DNA binding site.
dBS, dNTP binding site.
NNBS, non-nucleoside reverse transcriptase inhibitor binding site.
AS, active site.
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sequences). Some sequences were present in more than one
MSA and were discarded.
Thirty-five Colombian samples from hospitalized
symptomatic HIV-positive patients with viral loads over
1000 copies/ml were chosen for genotyping and were
analyzed so that the sequences from resistant isolates
could be included in the study (resistance data will be
published separately). These isolates were added to the
2,264 resistant isolate alignment to give a 2299 sequence
alignment. Accession numbers are: [GenBank:HM584982,
GenBank:HM584983, GenBank:HM584984, GenBank:
HM584985, GenBank:HM584986, GenBank:HM584987,
GenBank:HM584988, GenBank:HM584989, GenBank:
HM584990, GenBank:HM584991, GenBank:HM584992,
GenBank:HM584993, GenBank:HM584994, GenBank:
HM584995, GenBank:HM584996, GenBank:HM584997,
GenBank:HM584998, GenBank:HM584999, GenBank:
HM585000, GenBank:HM585001, GenBank:HM585002,
GenBank:HM585003, GenBank:HM585004, GenBank:
HM585005, GenBank:HM585006, GenBank:HM585007,
GenBank:HM585008, GenBank:HM585009, GenBank:
HM585010, GenBank:HM585011, GenBank:HM585012,
GenBank:HM585013, GenBank:HM585014, GenBank:
HM585015, GenBank:HM585016].
Variability analysis and shRNA design
A total of 48 shRNAs were found that could be used for
silencing HIV effectively based on the number of tar-
geted sequences in each MSA -targeted sequences are
those that matched the shRNA sequence- and the num-
ber of hits on more than one MSA (Additional file 1).
From these we sort out a reduced number that could
target the greatest number of sequences in order to
optimize their use in gene therapy. All of these shRNAs
fit the free energy criteria (≥-6.6 kcal/mol), which is
thought to be the most important factor for silencing.
Resistant isolates showed greater variability, which is
consistent with the calculated entropy values obtained
for each one. Table 2 shows the percentage of coverage
of each set of frequent shRNAs for each MSA. These
percentages were calculated as the number of sequences
that matched the exact shRNA sequence with respect to
the total amount of viral sequences included within
each MSA. Given the different number of total viral
sequences that were included in analyses, we used per-
centages in order to be able to compare results between
different MSAs. The number of viral sequences included
in the analyses (NSI) and the number of viral variants
(VV) -the latter including dominant and subdominant
viral variants– together give an indirect measure of
Table 2 MSA coverage by shRNAs
a MSA
b NSI
c VV
d W
e E
f SV
g ST-SV
h PC -SV (%)
i ST-DV
j PC-DV (%)
Pol Subtype B no Recombinants 747 35 1 1.36 11 712 95.31 588 78.71
Pol Group M plus Recombinants 1143 46 1 1.42 12 1088 95.18 913 79.88
Pol All Subtypes 1160 52 1 1.59 14 1102 95 916 78.97
Genome Subtype B no Recombinants 760 35 1 1.35 12 728 95.79 599 78.82
Genome Group M plus Recombinants 1153 46 1 1.41 12 1098 95.22 918 79.62
Genome All Subtypes 1169 52 1 1.60 13 1107 94.7 920 78.69
ZDV-3TC-EFV 1185 27 1 1.27 10 1169 98.65 1013 85.49
1201 30 2 1.52 14 1177 98 926 77.1
1348 53 3 1.94 13 1303 96.66 741 54.97
2299_resistant_isolates 1547 26 1 1.72 14 1552 98.84 1255 80.86
D4T-3TC-NVP 79 13 1 1.9 4 68 86.08 52 65.82
ZDV-3TC-ABC 52 10 1 1.78 3 41 78.85 33 63.46
ZDV-3TC-NVP 0 0 0 0 0 0 0 0 0
a MSA, multiple sequence alignment
b NSI, number of sequences included in the analysis (sequences having gaps and ambiguous codons were discarded)
c VV, total number of viral variants (these last defined as those having nucleotide changes with respect to HXB2)
d W, number of selected windows throughout the MSA, with a score threshold of 2 (windows satisfied specific requirements, see Methods)
e E, entropy per window
f SV, number of subdominant variants (are sequences that appear more than 4 times in an MSA, see Methods)
g ST-SV, sequences targeted by the group of subdominant variants.
h PC-SV, percentage of coverage by SV
I ST-DV, number of sequences targeted by the dominant variant.
j PC-DV, percentage of coverage by the dominant variant
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window is that whereby the greatest number of
sequences of a MSA could be included for the analyses,
a n dt h a ts h o w e dt h el e a s tn u m b e ro fv i r a lv a r i a n t s .O f
course, this would demonstrate that part of the viral
genome is not changing much and shows little world-
wide diversity -represented by the online available
worldwide sequences. Also the number of subdominant
variants (SV) for each window is an initial measure of
variability, for the perfect window should have the smal-
lest number of viral variants able to target most of the
sequences. This also happens with the number of
sequences that might be targeted by the group of subdo-
minant variants (ST-SV); this value indicates how many
sequences might be silenced by perfect sequence match-
ing and efficient silencing features, using the cocktail of
shRNAs directed to all these subdominant variants.
Regarding this variable, Table 2 shows that a cocktail of
shRNAs based on targeting the subdominant variants
might be able to target more than 90% of the sequences
(column PC-SV). Comparing PC-SV that can reach up
to 96% of sequences targeted, against PC-DV which
reaches well under 80%, it can be said that a cocktail of
shRNAs design based on subdominant variants has a
higher chance of targeting more viruses. Table 3 shows
the shRNAs that target sequences in more than one
MSA. In each MSA a set of sequences were eliminated
due to a high content of ambiguous bases in the ana-
lyzed window, or because they were repeated. The
scores are the result of different sequence features that
could improve silencing by enhancing the uploading of
the guide strand into the silencing complex (Additional
Table 3 Best shRNAs targeting sequences in more than one MSA
a HXB2 Coordinates
b shRNA Sequence
c Score
d Targeted MSAs
e Min_ST
f Max_ST
g Total
n2702-2725
h GCCTGAAAATCCATACAATACTCC 5 7,8,9,10 33 (7) 741 (9) 848
GCCTGAAAATCCATAtAATACTCC 6.5 2,9 6 (2) 223(9) 229
GCCTGAAAAcCCATACAATACTCC 5 2,9 4 (2) 62 (9) 66
n2333-2356 AGCAGATGATACAGTAgTAGAAGA 6 1,2,3,4,5,6 10 (1) 18 (6) 85
AGCAGATGATACAGTgTTAGAAGA 6 1,2,3,4,5,6 23 (1) 33 (4,6) 174
AGCAGATGATACAGTATTAGAgGA 3 1,2,3,4,5,6 12 (1,2) 15 (3,5) 82
AGCAGATGATACAGTAcTAGAAGA 6 1,2,4,5,6,10 6 (10) 17 (4,5,6) 81
AGCAGATGAcACAGTATTAGAAGA 7 1,2,3,4,5,6 21 (1,2) 31 (3,4,5,6) 166
AGCAGATGATACAGTATTgGAAGA 6 1,2,3,4,5,6 11 (1,2) 15 (3,4,5,6) 82
gGCAGATGATACAGTATTAGAAGA 7 1,2,3,4,5,6 16 (1) 27 (6) 139
h AGCAGATGATACAGTATTAGAAGA 7 1,2,3,4,5,6,10 21 (10) 920 (6) 4854
r2556-2579 AGtCCTATTGAaACTGTACCAGTA 2.5 9 1013 (9) 1013 (9) 1013
r2574-2597 CCAGTAAAATTAAAaCCAGGAATG 2 9, 10 60 (9) 74 (10) 208
h CCAGTAAAATTAAAGCCAGGAATG 3 9, 10 926 (9) 1267 (10) 3448
CCAGTAAAATTgAAGCCAGGAATG 2 9, 10 48 (9) 77 (10) 202
r2702-2725 GCCTGAAAATCCcTACAATACTCC 3.5 9 67 67 67
a Genome position according HXB2 numbering system
b In lowercase, nucleotides different from HXB2 reference genome
c Score is given by the accomplishment of specific sequence features
d Multiple sequence alignments numbered as follows:
1. POL_DNA_No_Recombinants.
2. GENOME_DNA_No_Recombinants.
3. POL_DNA_GroupM_Recombinants.
4. GENOME_DNA_GroupM_Recombinants.
5. POL_DNA_All_Subtypes.
6. GENOME_DNA_All_Subtypes.
7. ZDV-3TC-ABC.
8. D4T-3TC-NVP.
9. ZDV-3TC-EFV.
10. 2299_Resistant_Isolates.
e Min_ST, Minimun number of sequences targeted in an MSA. In parenthesis, the specific number of MSA, to which targeted sequences belong.
f Max_ST, Maximun number of sequences targeted in an MSA. In parenthesis, the specific number of MSA, to which targeted sequences belong.
g Total number of sequences targeted in all the MSAs.
h shRNA sequence corresponds to HXB2 reference genome.
nshRNAs from these regions were found in non-resistant MSA, despite some of them might target resistant viral sequences.
rshRNAs from these regions were found in resistant MSA.
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several sequences in highly divergent MSAs, with the
possibility of targeting more than one viral subtype and
even recombinants. The first three pairs of coordinates
have shRNAs that were identified in non-resistant MSAs
and the last three have shRNAs that were identified in
resistant MSAs. Scores are clearly different between both
groups, and similar within each group. shRNAs from
resistant isolates showed the lowest score values. As
expected, the dominant viral variant -usually matching
HXB2 reference genome– virtually targeted the greatest
amount of sequences. The others are virtually able to tar-
get other viral variants -subdominant and infrequent.
Statistical Analyses
Multiple comparisons grouped non-resistant MSAs
apart from resistant MSAs. There were no statistical dif-
ferences (p > 0.05) within non-resistant MSAs when
comparing weighted average scores, but significant dif-
ferences (p < 0.05) were observed between non-resistant
MSAs in comparison to resistant MSAs. In addition,
there were significant differences within resistant MSAs
with respect to both windows of 2299 Resistant Isolates
MSA and ZDV-3TC-EFV window 2. Table 4 shows the
letter code (APA) obtained for each comparison. MSAs
that do have significant differences with respect to a
M S A sa r et h o s ew h o s el e t t e rc o d ea p p e a r sb e n e a t h
them. In the same way they do not have significant dif-
ferences with those MSAs whose letter do not appear
beneath. Figure 2 is a box-plot that shows the non-sym-
metric distribution and atypical values of the score for
each MSA. The diagram shows a clear clustering
between non-resistant and resistant MSAs. Non-resis-
tant MSAs demonstrated better scores, much higher
than those obtained for resistant MSAs. Outliers and
extreme values seem to make a pattern within the group
of non-resistant MSAs. When comparing the proportion
of sequences that can be silenced by designing shRNA
against the most frequent variant, there were no signifi-
cant differences (p > 0.05) within non-resistant MSAs.
From resistant MSA, only ZDV-3TC-EFV_w1 MSA
showed significant differences to all MSAs. Significant
differences (p < 0.05) were found between both resistant
and non-resistant MSAs (Table 4). Figure 3 shows the
distribution of proportions of dominant and subdomi-
nant viral variants within each MSA. Entropy and Score
values showed a negative, indirect and 99% significant
correlation, with r = -0.378 (p < 0.01). Resistant MSAs
which had the highest entropy values showed no prefer-
ence for score values, which is in accordance with the
fact that these MSAs showed much more polymorph-
isms than non-resistant MSAs (Figure 4).
Blast
Using BLAST, eight out of forty-eight shRNAs were
found in the selected databases. Results are shown in
T a b l e3 .N oh i th a d1 0 0 %o v e r l a p ,a n do v e r l a pw a s
toward the 3’ terminal end of the shRNA (Additional
file 3).
Discussion
This is the first in silico approach to novel shRNA
design based on the scored search of a group of
sequences directed at silencing the dominant and sub-
dominant most frequent wild type and mutant RT var-
iants, targeting conserved regions. We developed an
algorithm that followed previously published sequence
parameters from effective shRNAs, using a free energy
cut-off and specific sequence features [24,25]. No cur-
rent approach targets frequent viral variants simulta-
neously; instead, it is usual to target several conserved
regions with one sequence. The trouble is that for each
of these regions, other frequent variants that do not
match the reference genome sequence HXB2 need to be
considered. Similar interesting works have been underta-
ken also analyzing publically available sequences, such as
McIntyre et al. 2009. However, these differ from ours in
that they neither searched for subdominant viral variants
and/or infrequent viral variants, nor searched for
shRNAs able to target resistant viruses that emerged
under a specific antiretroviral selective pressure. Also,
they do not describe in detail their in silico analyses; the
features for silencing activity they evaluated, the filters
or threshold they used, whether they included a free
energy cut-off, their approach to ambiguities (UIPAC
letter code), whether they used all the sequences, how
they analyzed sequence quality in their MSAs, etc. They
did design shRNAs of different lengths directed toward
HXB2 reference genome, that overlaps within one of
our regions -emphasizing the conservation of this part
of the viral genome- however, those molecules do not
match our subdominant variants. Our results identified
a greater number of viral variants that any other study.
shRNA design is difficult, owing to the multiple
requirements for achieving efficient silencing in vivo,
and to all the parameters that must be carefully fol-
lowed. Available programs are usually directed towards
siRNA rather than shRNA design [26], and it has been
shown that these programs do not always correctly pre-
dict the silencing efficiency of shRNAs [27]. Online
tools do not allow for more than one aligned sequence
to be used, but several aligned sequences are necessary
for designing silencing molecules against error-prone
viruses such as HIV. Throughout the HIV-1 genome, we
identified the less variable regions that showed the best
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Page 6 of 17Table 4 Multiple Comparisons for Score, and Proportion of dominant variants
MSA 2299
Resistant
Isolates w1
2299
Resistant
Isolates w2
AZT-
3TC-
ABC
D4T-
3TC-
NVP
GENOME
DNA All
Subtype
GENOME DNA
GroupM plus
Recombinants
GENOME DNA
No
Recombinants
POL DNA
All
Subtypes
POL DNA
GroupM plus
Recombinants
Pol DNA No
recombinants
ZDV-
3TC-EFV
w1
ZDV-
3TC-
EFV w2
ZDV-
3TC-EFV
w3
Assigned
letter
group
(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M)
Mean
aScore
ABK
L
ABK
L
ABCDKL
M
ABCDKLM ABCDKLM ABCDK
LM
ABCDKLM ABCDKL
M
ABL ABKL
b0 KK K K K K K K K A B E F
GHIJK
L
b1 MM M M M M M M C D E F
GHIJL
M
M
a. Weighted average of the score was used for multiple comparisons between de MSAs
b. In the comparisons of the proportion of dominant variants, number 1 represents the dominant viral variants while number 0 represents the rest of viral variants (subdominant and infrequent).
For weighted average score, a multiple comparison Student t-test was used to evaluate mean equality between each pair of groups. The MSA was assigned as the segmenting categorical variable and the score was
the continuous variable for which the mean was calculated. For the comparison between pairs of proportions of dominant variants, a Z-test was used. The MSA was assigned as the segmenting categorical variable,
and the proportion was assigned the categorical variable that revealed the presence or absence of the event of interest. In the second and third rows appear the corresponding letters of the groups that showed
significant differences with the MSA of the column. In both cases p values were corrected with Bonferroni-Dunn test with an alpha of 0.05. See Methods, for further understanding on how weighted average scores
were calculated.
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Figure 2 Score Distribution among MSAs. No scores under 2.0 are shown because this score value was the threshold used for selection by
the algorithm. Circles indicate outlier values and stars indicate outlier extreme values.
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Figure 3 Proportion of dominant or most frequent viral variants. The total number of sequences is the amount of sequences that the
algorithm analyzed. In the case of MSAs that have more than one window, the total number of analyzed sequences may be different. Other
viral variants correspond to subdominant or totally infrequent viral sequences.
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Page 8 of 17silencing predicting features. However, MSAs revealed
that there is at least between 20.12% to 21.31% of naïve
isolates, and between 14.51% to 45.03% -percentages
result from subtracting the table values out of 100%- of
resistant isolates that will not be targeted using solely
the dominant viral variant (Table 2). For that reason tar-
geting multiple genome regions with one sequence for
each will not solve this problem, because each region
will have different untargeted naturally occurring var-
iants. Any design strategy based on consensus shRNA
sequences is susceptible to viral escape in terms of long-
term silencing, particularly in an HIV-1-infected human.
HIV variability underlies the fact that key target selec-
tion is of utmost importance. The most frequent or
dominant shRNA (one sequence) in all the alignments
fell between 63.46% and 85.49% of the viral sequences
with an average value of 75.20% (Table 2). This is
consistent with previous findings in which targeting a
single region resulted in rapid emergence of resistance
by means of selecting subdominant variants -those that
remained untargeted [28]. Achieving a higher silencing
could be obtained by targeting subdominant variants
from the same region like the subdominant variants we
found (Table 3 and Additional file 1. Ideally, all the
viable changes in each targeted conserved sequence
must also be targeted in order to achieve life-long silen-
cing. For this we first attempted to analyze further viral
variability on the basis of protein function or biological
significance, which is thought to show the lowest varia-
bility. From the selected regions based on protein func-
tion, only region number 2 of RT conserved domain
provided results (Table 1 and Table 3). This was prob-
ably because we were not merely looking for a con-
served region, but a conserved region that met specific
Figure 4 Information Entropy and Scores correlation. The ellipses highlight the score distribution for resistant MSAs (a.) and the correlation
observed for non- resistant MSAs (b.).
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Page 9 of 17requirements such as free energy values and sequence
specific features. This was based on the fact that
shRNAs that are perfectly matched with their target
sequences do not necessarily achieve 100% silencing.
Nonetheless, our shRNAs targeted only two regions in
PR and one in RT, highlighting the conservation of these
regions despite analyzing complete genome sequences;
complete genomes provided the same windows. It is
interesting that all the HIV-1 group M sequences behave
within the same limits of variability, and the inclusion of
recombinants did not affect the results. High scores were
predominant in these sequences, implying that within the
selected regions changes are allowed preferably in the
same positions, not randomly. Highest scores were not
reached; this means that intrinsic HIV-1 sequence char-
acteristics and variability are an obstacle to expecting
specific silencing sequence features in shRNA molecules.
In fact, reaching the highest score demands for a highly
conserved region in which changes are limited to certain
positions and certain nucleotide changes. The latter is
due to the fact that there are multiple sequence features
that need to be satisfied throughout the silencing mole-
cule in such a way that increasing variability would
reduce the probability of achieving them. Differences
were only significant when analyzing resistant MSAs.
Low scores of these sequences are attributable to the
degree of polymorphisms that seem not to have any pat-
tern, and to drug selected mutations. Changes can occur
almost in any place of the 23 nt window with differences
in frequency per position, but with no apparent restric-
tion. That’s why resistant MSA showed the highest
entropy values with the lowest scores. Recently, Schop-
man et al. [29] showed that targeting common resistant
variants that emerge under silencing therapy decreased
viral escape, but then new routes of evading silencing
were used by the virus. This is explained by our analyses,
which showed that there is over 20% variability that the
virus can use to escape, without any selective pressure
(non-resistant MSAs). Resistant MSAs showed the cap-
ability of the virus to mutate much further beyond this
20%. In fact, non-resistant MSAs were grouped together
and apart from resistant-MSAs (Table 4.). Window 1 from
ZDV-3TC-EFV was different from all the other MSA
(resistant and non-resistant) in dominant viral variants,
and W3 from the same MSA was different also in subdo-
minant viral variants. These results are consistent with the
fact that W1 dominant viral variant is different from
HXB2 reference sequence and also with the fact that W3
had the lowest entropy value, which is the same as saying
that it showed the highest variability. Resistant-MSAs con-
stitute an insight to understand virus evolution; nonethe-
less we doubt those to show the true limits. In any case,
targeting the dominant and subdominant viral variants for
each region may reduce this set of viable changes.
We did not find any other genome region to be tar-
geted, probably due to some of the parameters used
such as “number of sequences” in which regions that
are not well represented by a certain number of
sequences are discarded. Another reason is that other
stringent conditions besides sequence conservation were
assessed. Unfortunately, genome ends are underrepre-
sented, which leaves long terminal repeats (LTRs) and
other terminal regions outside of the study. LTR is
thought to be a good region for this type of strategy,
but the variability of this region cannot be addressed
accurately due to the relative small number of complete
sequences present in the databases. There is another
explanation for not having found shRNAs for key
regions within the RT conserved domain. For example,
the conserved nucleotide positions for the YMDD motif
ranges from 1 to 8 out of 12, in the nucleotide reference
MSA from the pol gene (Los Alamos HIV Databases).
The amino acid reference sequence for the window with
the fewest variants was WPLTEEK, which can be
formed by 512 different nucleotide sequences. The
mutations throughout the reference Pol polyprotein
MSA (Los Alamos HIV Databases) are W24R, P25LTS,
T26SA, E27KAGR, E28K and K29ER, and these collec-
tively give 286,654,464 possible nucleotide combinations.
Another reason could lie in the three nearby amino
acids (either to the left or to the right of the motif),
which can be encoded by more than two codons due to
the redundancy of the genetic code.
Altogether, our group of shRNAs might be able to
silence at least 94% of the sequences present in the
alignments, just by perfect matching. This means that it
is possible to target almost every virus at least once,
with a selective group of shRNAs. Untargeted sequences
can probably be targeted including frequent shRNAs
from a different region, as is shown in Figure 5. Though
it must be considered that an uncommon sequence var-
iant either was the dominant one in a patient, or was
the amplified quiasispecie, or it could have also been a
sequencing error. Since evolution depends on time,
intrapatient viral evolution can turn rare variants into
dominant ones, so the selection of frequency threshold
could not be picked too high. Because of this, sequences
that appeared 4 or more times in an alignment were
named frequent sequences. Frequent variants -including
both dominant and subdominant- usually have higher
fitness, so rare variants may be less pathogenic and per-
haps controllable by the host immune system. shRNAs
found in this study have high silencing scores, meet the
energy threshold needed for efficient loading into RISC
complex, and target most of the viral sequences ana-
lyzed in silico. Free energy threshold is fundamental for
guide strand selection and mounting into the RISC
complex, increasing the silencing efficiency of our
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tein phosphatase 2C, mRNA, should be tested in vitro.
This is done in order to address the real silencing of the
genes when using the set of shRNAs that have 17 bp of
identity with this human gene, 15 of which are directly
related with silencing (two of them correspond to 3´
terminal overhangs). shRNAs with 20/20 identities with
a BLAST hit should be avoided, unless proven to be
safe.
In 2004, an siRNA against nef was used to inhibit HIV-1
in vitro, however in these assays, several weeks later escape
mutant viruses emerged. That was one of the first studies
to propose that virus variability should be addressed with a
combination of siRNAs [30] Escape happened because the
selected target sequence is biologically dispensable, a fact
that should not be ignored even though the target was not
thought to be nef itself, but all the RNA viral variants
which are supposed to have this sequence. Now this under-
lines the importance of including much more biological
information criteria for target selection than simply
sequence conservation or the presence of a sequence in
multiple viral transcripts. In fact, we found no conservation
in any of the 21 nucleotides of the nef sequence used,
throughout an MSA (data not shown). In other words,
silencing was directed against an uncommon or subdomi-
nant variant of the virus, a fact that could have played a
role in resistance development. However, it is important to
highlight that HIV-1 silencing has been achieved in in vivo
mouse models. Silencing was observed in a mouse model
systemically infected with a combination of siRNAs
Figure 5 Silencing Model. Targeting dominant variants from two or more regions leaves several subdominant viral variants untargeted. The
optimal approach would be a cocktail of carefully selected molecules targeting dominant as well as subdominant variants from more than one
conserved region. The figure shows a schematic representation of HIV-1 genome and an MSA of HIV-1 pol gene, in which the strategy of
silencing is drawn. Some sequences would be targeted by two shRNAs, some just by one, and a few would not be targeted at all, but are not
frequent. W1 and W2 represent the hypothetical targeted regions, where “W” stands for “window”.
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specific siRNAs [15], and no evidence of viral escape
mutants was observed. Furthermore, a mouse model was
engrafted with human hematopoietic stem cells that were
previously transduced with a lentiviral vector carrying a
shRNA against nef. While transduction efficiency in this in
vivo model was reduced, ex vivo transduction of mature
CD4 (+) cells lead to wild type HIV-1 resistant T cells in
vivo [20]. Now, even though certain studies have shown
the emergence of resistant variants, our results raise the
question whether they always result from “resistance” to
RNAi therapy or whether they are naturally occurring
uncommon variants that are being selected rather than tar-
geted. So even though there was no evidence of resistance
in the first mouse model–and despite the fact it was clearly
shown that the silencing effect is sequence specific, regard-
less of the type of infection used (systemic or ex vivo) and
regardless of the time an experiment is assessed–it cannot
be said for sure that resistance wouldn’t have occurred
later. Even when assessing resistance was not the aim of
these studies, it constitutes a threat for therapy outcome.
In fact, resistance against HAART inhibitors arises in many
human cases within a few years of initiating therapy,
usually 2-4, depending on different variables [7,31-34].
Then, longer periods of time in an animal model are there-
fore needed to evaluate the emergence of resistance or the
inhibition of virus replication, especially since treatment
has to be life-long. Our target was RT because it cannot be
deleted from the genome and is the main source of virus
variability. Since it is a HAART target, information about
mutations induced under selective drug pressure is avail-
able [33,35-38]. Reverse transcription is a prerequisite for
viral integration and infection of other cells, so its silencing
would reduce the number of cells that become actively and
latently infected, preventing the establishment of more
HIV cell reservoirs.
Several groups have also designed silencing molecules
within our same pol region, confirming the importance
of this region as an HIV target [16,19,21,23,30,39,40].
However, these previous molecules do not exactly begin
from the same position as ours, have different lengths,
and are only directed to silence viruses that match the
dominant HXB2 reference genome sequence or specific
mutant viruses that emerge during RNAi experiments in
prolonged cell culture. We compared our dominant
shRNAs to 100 previously published pol-directed silen-
cing molecules and none of them was found to be iden-
tical, but some do map really near within the virus
genome (data not shown). The nearest previous pub-
lished molecule (2328-2346 with respect to HXB2) [19]
maps 5 nt downstream of our targets against non-resis-
tant isolates (2333-2356 with respect to HXB2). Seven
other molecules were designed from position 2326 to
2360 with respect to HXB2 [23], and three more targets
were designed in region 4752 to 4775 [23], overlapping
our shRNA for non-resistant isolates that was identified
when analyzed with no score restriction. Our molecule
mapped within position 4747- 4770 with respect to
HXB2 (Additional file 2). There are neither previous
reports concerning shRNAs targeting viruses resistant to
current first line antiretrovirals, nor reports about
shRNAs targeting other dominant or subdominant viral
variants within the same genome region. To target
viruses resistant to certain antiretrovirals or to certain
line of antiretrovirals with RNAi while taking them, or
to target dominant and subdominant viral variants
simultaneously, may hypothetically impede viral escape
due to a major reduction in the possible available
nucleotide changes that are not deleterious to the virus.
This type of approach might cover many more viral var-
iants than using just one strategy, but it will not solve
economic issues and side effects concerning life-long
HAART.
Conclusions
The emergence of resistant viral variants is an inconve-
nience that must be addressed carefully, particularly in
the case of using shRNAs since they normally work in a
s e q u e n c e - s p e c i f i cm a n n e r .I nt h i ss t u d yw ei d e n t i f i e d
dominant and subdominant frequent viral variants
representing the set of naturally occurring changes that
are observed in the viral population that has been
sequenced world-wide, and we designed shRNAs against
these. We found that in order to cover all the viral
variability to impede viral escape, we will need to use
too many silencing molecules, which is not clinically
feasible. Even in the absence of a selective pressure such
as antiretrovirals, there are plenty of polymorphisms
that can occur throughout the viral genome that can
allow the virus to escape RNAi therapy. In addition,
drug selective pressure is capable of inducing even more
unusual changes. Although it is difficult to determine
the exact mechanism by which it is possible to comple-
tely avoid viral escape, what is important now is that we
have identified most of what we have to set upon. Our
shRNA cocktail was developed based on the viral varia-
bility we found, and there is chance that it could be
used alone (cocktail) or as a complement to HAART.
Several authors have also proposed a cocktail of shRNAs
to target HIV-1, but our cocktail is different in that it
was designed to target dominant as well as subdominant
viral variants. Long-lasting silencing for humans seems
much more possible with this complete approach. Our
results point towards the conclusion that viral popula-
tion is modeled by selective pressures, since it was pos-
sible to find shRNAs for most of the regimens (it was,
however, difficult for ZDV-3TC-NVP). Special attention
must be taken regarding the fact that selective pressures,
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virus to mutate within the limits of resistance to antire-
trovirals, since most changes are non- deleterious.
Further studies are needed to find regimens with resis-
tance patterns that can be specified and better con-
trolled using the fewest number of shRNAs. Proving real
in vivo efficiency in combination therapy, as well as
identifying off-target and non-specific off-target effects
of the shRNAs, is absolutely required before starting any
therapeutic approach.
Our study is the first in identifying naturally occurring
and induced nucleotide changes in the virus, based on
data from viruses modeled by natural selection from
natural hosts (humans) and from viruses modeled by
drug selective pressure in treated patients.
This work is important to understanding the complex-
ity of HIV-1 variability, in order to be able to target it
effectively. Indeed, nucleotide substitutions have
occurred under RNAi selective pressure, but we have
shown in this study that there are much more nucleotide
changes that can occur which may result in viral escape.
Different approaches might work while trying to address
viral ability to escape RNAi therapy, but undoubtedly the
more information we know about the mechanisms the
virus uses to do so, the more we can do about it.
Methods
Conserved regions and prevalent drug-resistant
mutations: target sites
Pol polyprotein AAB50259.1 from the HXB2 reference
sequence was used as query against the conserved
domain database (CDD) of NCBI [41] in order to iden-
tify catalytic residues, residues involved in DNA binding,
dNTP binding, or active site residues with no other
annotation. The map of coordinates from the HXB2
reference sequence accession number K03455 (gi|
1906382|gb|K03455.1|HIVHXB2CG human immunode-
ficiency virus type 1 (HXB2), complete genome; HIV1/
HTLV-III/LAV reference genome), available at Los Ala-
mos HIV databases http://www.hiv.lanl.gov, was used to
find the exact positions of selected regions in MSAs
using the sequence as a guide. The complete genomes
were also assessed in order to identify other possible
targets within conserved regions outside of the pol gene.
In addition, high prevalence resistance mutations were
selected from the “Mutation Prevalence According to
Subtype” web page http://hivdb.stanford.edu/cgi-bin/
MutPrevBySubtypeRx.cgi from the Stanford HIV Drug
Resistance Database (HIVRT&PrDB) http://hivdb.stan-
ford.edu/[42]. Mutations which were located within the
selected regions of the conserved domain were
preferred.
Sequence retrieval and MSAs
Sequences from resistant isolates were retrieved from
HIVRT&PrDB by a therapy criterion that consisted of dif-
ferent combinations of three antiretrovirals, two nucleo-
side analog reverse transcriptase inhibitors (NRTI) and
one non-nucleoside analog reverse transcriptase inhibitor
(NNRTI). These sequences were not grouped by a specific
regimen; instead they were grouped together as sequences
from resistant viruses that emerged under different first
line regimens. Duplicates and repeated sequences were
eliminated using the Elim Dupes tool http://www.hiv.lanl.
gov/content/sequence/ELIMDUPES/elimdupes.html from
Los Alamos HIV databases. Sequences were further pro-
cessed to eliminate foreign characters not compatible with
FASTA format (e. p. “~”), and were then aligned to gener-
ate an MSA. In addition, first-line regimens that are used
in Colombia were selected from the “National Resolution
No. 3442-2006 for the care of HIV-infected patients”,
approved for treatment of HIV infection in Colombia by
the Ministerio de Protección Social [43]. This was done in
order to retrieve sequences generated by the specific drug-
selective pressure induced by each regimen in our country.
The regimens were zidovudine-lamivudine-efavirenz
(ZDV-3TC-EFV), which is normally the first choice,
zidovudine-lamivudine-nevirapine (ZDV-3TC-NVP), zido-
vudine-lamivudine-abacavir (ZDV-3TC-ABC) and stavu-
dine-lamivudine-nevirapine (D4T-3TC-NVP), which are
also first line regimens. All of these select M184V muta-
tion. Sequences were aligned by HMM (Hidden Markov
Models) model HIV-1/SICcpz [44] into four independent
MSA, one for each regimen. MSAs were generated using
the HIVAlign tool from Los Alamos HIV databases, which
is an implementation of the HMMER package http://
http://www.hiv.lanl.gov/content/sequence/HMM/HmmA-
lign.html, and sequences were codon-aligned with Gene
Cutter http://www.hiv.lanl.gov/content/sequence/GENE_
CUTTER/cutter.html. HXB2 was included in each MSA
to identify the selected regions. MSAs were further edited
manually using MSA editors Bioedit and eBIOX, and ana-
lyzed in CLC DNA Workbench http://www.clcbio.com
(Aarhus, Denmark).
Sequences from naïve isolates were retrieved from Los
Alamos HIV databases. MSAs were generated as men-
tioned and downloaded from this database. In order to
address the impact of virus variability in the aim of the
study, different type of MSAs were downloaded from
the database (i.e. Subtype specific, pol gene specific, with
and without recombinants, complete genomes, all sub-
types, whole group M). HXB2 was also included in each
alignment and MSAs were also manually edited.
Additionally, 35 Colombian isolates from sympto-
matic HIV-positive patients were included in the
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t h eM S Ao ft h en o n - r e g i m e n - s p e c i f i cr e s i s t a n tv i r a l
sequences. Only samples with written informed con-
sent, complete clinical history and viral loads over
1000 copies/ml were included. RNA was extracted
using the semi-automated Nuclisens Minimag and
Nuclisens Extraction Kit according to the manufac-
turer’s instructions (Biomerieux, Marcy l’Etoile,
France). HIV was genotyped with a commercial TRU-
GENE HIV-1 kit (Siemens Diagnostics, Deerfield,
USA), and fasta sequences were further analyzed with
HIVdb software from HIVRT&PrDB. Quality assess-
ment and Calibration Population Resistant (CPR) tools
were used to evaluate probable sequencing errors and
mutation prevalence, respectively.
Variability analysis and shRNA design
A Bioperl-based algorithm was developed to identify
nucleotide changes throughout the multiple MSAs. The
algorithm was developed to identify all the existing viral
sequence variants and their frequencies throughout an
MSA, while evaluating their silencing efficiency based
on free energy and entropy calculations, in addition to a
score that represented how many specific sequence fea-
tures they met. The HIV genomes were processed in
order to extract potentially useful sequences for the
synthesis of shRNA
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molecules. The genomes were first aligned using
HMM (see sequence retrieval and MSAs) and the MSAs
were scanned using sliding windows of 23 bp. For each
window, the information entropy as defined by Shannon
[45] was calculated:
Where n is the number of different sequences within
each window, πi is the proportion of the i-th sequence (i.e.
the number of times this sequence appears in the window
divided by the number of sequences in the alignment),
and Hp is the information entropy of the p-th window.
Only windows with information entropy below two
-allowing viral variability to be studied- and with more
than 40% of informative sequences (i.e. not entirely com-
posed by gaps) were accepted, avoiding windows that were
too variable, and two sets of conditions were evaluated on
every different sequence of the window. First, we evaluated
mandatory conditions, accepting only sequences:
￿ With less than 10% gaps,
￿ No gaps in the middle of the sequence,
￿ No ambiguous characters (i.e.o n l yA ,C ,Ta n dG
accepted),
￿ No G or C stretches of 4 bp or more in length,
￿ No T stretches of 3 bp or more in length,
￿ Starting with T or C,
￿ With GC percentage between 30 and 50,
￿ ΔG measured in the 5’ l a s t7b po ft h es e n s e
sequence above -6.6, and
￿ ΔGm e a s u r e di nt h e5 ’ l a s t6b po ft h ea n t i s e n s e
sequence above -6.6.
The ΔG were calculated as described by Freier et al
[46]. Afterwards, we evaluated a score only on accepted
sequences, defined as a sum of differentially scored
properties
￿ The sequence starts with AA, AT, TT or TA: +0.5,
￿ The sequence ends with AA, AT, TT or TA: +0.5,
￿ The AT count of the 15-21 position range is at
least 4: +1, or more than 4 (+1 for every additional
A or T in the range),
￿ The 21st position is A or T: +1,
￿ The 5th position is C or G: +0.5,
￿ The 7th position is G: +0.5,
￿ The 13th position is A or T: +0.5,
￿ The 16th position is T: +0.5,
￿ The 8th position is C and the 9th position is A: +1,
￿ The 10th and 11th positions are C: +1,
￿ The 12th position is T and the 13th position is G: +1,
￿ The 15th position is G and the 16th position is A: +1,
￿ The 19th position is T and the 20th position is A: +1,
￿ The 20th position is T and the 21st position is A: +1,
￿ The GC count is below 11: +1,
￿ The 21st position is G or C: -1,
￿ The 5th position is T: -0.5,
￿ The 6th position is T and the 7th position is A: -1,
￿ The 8th position is T and the 9th position is A: -1,
￿ The 10th and the 11th positions are G: -1,
￿ The 11th position is G and the 12th position is C:
-1, and
￿ The 19th position is G and the 20th position is A: -1
Unique sequences with a score equal or greater than
two were accepted because they had at least two effi-
cient sequence specific silencing features, an advantage
over silencing molecules that are made to follow only a
sequence specific silencing; higher score thresholds
would have resulted in the elimination of too many
sequences per window leaving less than an 80% of the
initial amount, rendering further analyses not worthy.
Only windows with at least 80% of sequences accepted
were used in further analyses. Within each accepted
window, sequences that appeared 4 or more times were
named as subdominant viral variants, viral variants
meaning different from reference HXB2 sequence. No
statistical approach was undertaken to asses this
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nucleotide changes that could have been sequencing
errors, but at same time trying to rescue very infrequent
but viable and possible ones accepted within the limits of
virus evolution. Dominant viral variant, refers to the viral
variant that appears the most, but in this case it may be
exactly the same as reference HXB2 sequence. A window
might have one or more dominant variants when there
are sequences that appear a similar number of times as
the dominant viral variant in a MSA. All the accepted
sequences in the accepted windows were searched
against the NCBI’s Human RNA database using BLAST
[47] with an e-value threshold of 0.1. Sequences were
also searched against the Human genomic sequences in
order to search for a potentially transcribed sequence not
identified so far as mRNA, with identical parameters.
The algorithm evaluated the predicted efficiency of
silencing in the DNA viral sequence to be transcribed as
a guide strand (Figure 6). The algorithm source code is
freely available online via GPL license in order to be
used and improved by others, at http://bioinf-mac.uni-
andes.edu.co/shrna
Statistical Analyses
Data was organized considering each MSA as an inde-
pendent group, and statistical analyses were performed
with SPSS for windows package V 8.0.0 (SPSS Inc., IBM,
Chicago, Illinois). A descriptive analysis was performed
to describe quantitative variables for which weighted
average values were calculated, and qualitative variables
were expressed as frequencies. For all the multiple com-
parisons, the non parametric Bonferroni-Dunn correc-
tion test was used. Weighted average scores obtained for
each MSA were compared in order to address if scores
were significantly different within all categories using a
Student t-test (p < 0.05, a = 0.05). These weighted aver-
age scores were calculated as the average score for each
MSA, but it was weighted with respect to the number of
sequences that showed that score. This is why it is a
“weighted” average score. The Spearman correlation
coefficient was used to address Score-Entropy non-cau-
sal association (p < 0.01, a = 0.01). Differences in the
proportion of sequences that could be targeted by the
most frequent variant of each MSA were also addressed
with a Z-test (p < 0.05, a = 0.05). Comparisons were
made with no discrimination between resistant and non-
resistant viral sequences. For MSAs for which more than
one window was selected by the algorithm, each window
was treated independently.
Additional material
Additional file 1: Frequent shRNAs in all the MSA. The table shows all
the frequent shRNAs (48), each of which occurred at least 4 times in an
alignment.
Additional file 2: Data File. There are two sheets that correspond to
raw data. The first sheet has the results obtained using a score threshold
of 2, and the other sheet has the results obtained with no score
threshold. Notice that in this second sheet, the same windows appeared
that were selected in the first sheet, in addition to new windows that
were initially discarded due to score threshold. All these new windows
passed the first filters in which free energy calculation is included.
Additional file 3: BLAST Hits Description. Complete information for
each BLAST hit found in the databases is described.
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